Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
Healthcare
$2.30 +3.52%
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
52W Low $2.14High $11.88
Volume 0.07M
Average 0.08M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$46.15M
FY 2025 · Annual
Net Income
-$43.44M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.12M | 0 | 0 | 0 | 13K |
| Gross Profit | (1.12M) | 0 | 0 | 0 | (13K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 119.62M | 11.76M | 11.71M | 12.34M | 30.75M |
| Selling, General & Admin | 49.08M | 2.24M | 1.76M | 42.92M | 15.39M |
| Operating Expenses | 168.7M | 14.01M | 13.46M | 55.26M | 46.14M |
| Depreciation & Amortization | 1.12M | 0 | 0 | 0 | 13K |
| EBITDA | (169.84M) | (15.25M) | (14.01M) | (58.77M) | (41.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (169.82M) | (14.01M) | (13.46M) | (55.26M) | (46.15M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 1.32M | 0 | 0 | 5.49M | 0 |
| Interest Expense | 0 | 235K | 687K | 0 | 1.44M |
| Other Income / Expenses | (1.14M) | (1.48M) | (1.24M) | (3.51M) | 2.71M |
| Income Before Tax | (170.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.01M | 0 | 0 | 0 | 0 |
| Net Income | (171.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (63.00) | (50.62) | (42.09) | (11.73) | (2.85) |
| EPS (Diluted) | (63.00) | (50.62) | (42.09) | (11.73) | (2.85) |
| 2.73M | 3.33M | 4.52M | 5.01M | 15.27M | |
| 2.73M | 3.33M | 4.52M | 5.01M | 15.27M |
KLRS Earnings Waterfall · TTM
NASDAQ:KLRS · Revenue to Net Income
Key Ratios
EPS$-2.15
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-2.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$44.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.15, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Oct 26, 2026 |
How much revenue does KLRS generate?
Kalaris Therapeutics Inc (KLRS) reported $0.00 of revenue in fiscal 2025.
Is KLRS profitable?
Kalaris Therapeutics Inc (KLRS) reported -$43.44M of net income.
Continue the stock analysis
Jump to another research area for this company.